Osteosarcoma is the most common malignant primary bone tumor for which pertinent preclinical models are still needed to develop new therapeutic strategies. As osteosarcoma growth is strongly supported by bone resorption, previous studies have inhibited the cytokine receptor activator of nuclear factor-kB ligand using antibodies or recombinant proteins. However, its expression has not yet been inhibited using genetic approaches using small interfering RNA. To optimize the delivery of small interfering RNA to its cellular target and demonstrate their efficiency in vivo, two new osteosarcoma models expressing the firefly luciferase enzyme were developed. These luciferase-expressing osteosarcomas showed conserved osteolytic and osteogenic activities in mice and were detectable by in vivo bioluminescence imaging. In comparison with measurement of tumor volume, bioluminescence analysis enabled earlier tumor detection and revealed extensive cell death in response to ifosfamide treatment. Finally, by targeting the luciferase expression into osteosarcoma, we established a protocol for in vivo administration of small interfering RNA combined with cationic liposome.
Introduction
Osteosarcoma, defined as a rare malignant disease, is the most common primary bone tumor in both children and young adults, with a median age of 18 years at diagnosis. 1 Its development is characterized by the formation of immature bone or osteoid tissue by tumor cells, and is frequently associated with para-tumoral osteolysis causing painful bone fragility, frequently resulting in bone fractures. After initial diagnosis made by anatomopathology on open biopsy, treatment consists of tumor resection by surgery combined with pre-and postoperative chemotherapy (high-dose methotrexate, cisplatin and doxorubicin with ifosfamide in the post-operative phase). Over past several decades, the survival rate has improved, currently reaching approximately 70% at 5 years, but only 25% when lung metastases are detected at diagnosis. 2 Moreover, osteosarcoma patients who poorly respond to chemotherapy have a high risk of relapse. 3 Therefore, a need for new therapeutic options still exists. 4 The development of primary bone tumors and bone metastases within the bone microenvironment is associated with a vicious cycle between tumor proliferation and bone resorption. 5 This osteolysis is largely due to the activation and differentiation of osteoclasts through the interaction of the cytokine receptor activator of nuclear factor-kB ligand (RANKL or tumor necrosis factor superfamilly member 11) with its receptor RANK. Several studies have demonstrated in various bone metastases models that blockade of RANKL using soluble decoy receptors resulted in an inhibition of osteolysis and slowdown of tumor progression (by soluble RANK [6] [7] [8] or by the decoy receptor osteoprotegerin [9] [10] [11] [12] ). The reduction in tumor incidence and growth by RANKL inhibition has also been demonstrated in osteosarcoma models. 13, 14 As blocking RANKL was proven to be effective in several in vivo models, a fully humanized monoclonal antibody directed against RANKL (Denosumab) has been developed for clinical use, and is currently being evaluated in several clinical trials for the treatment of patients with lytic bone lesions secondary to multiple myeloma, prostate or breast cancer. 15 Currently, RNA interference (RNAi) is being explored as a potential treatment for cancer. 16, 17 So far, only few preclinical studies have tested the affect of injection of RNAi molecules on bone tumor models. Moreover, these studies have predominantly decreased the expression of genes associated with cell cycle. [18] [19] [20] [21] In osteosarcomas, one way to evaluate the therapeutic potential of small interfering RNA (siRNA) would be to target expression of RANKL in comparison with its blockage by antibody. However, the main challenge for the successful use of siRNA in vivo is to achieve an efficient delivery of these molecules to the target tissue without off-target effects. [22] [23] [24] This is the purpose of this study. Osteosarcoma models that have been established in our laboratory, 13, 25 were modified to stably express the firefly luciferase using lentiviral gene transfer, then the luciferase expression was targeted with siRNA combined with the cationic liposome RPR209120 2-{3-[Bis-(3-amino-propyl)-amino]-propylamino}-N-ditetradecyl carbamoyl methyl-acetamide and DOPE (dioleyl phosphatidyl ethanolamine; Avanti Polar Lipids) 26, 27 to determine the optimal delivery method for siRNA in osteosarcoma models.
Materials and methods
Osteosarcoma cell culture Cells (OSRGA) derived from a rat transplantable osteosarcoma model originally induced by radiation 28 were cultured in Dulbecco's modified Eagle medium (Lonza, Verviers, Belgium) supplemented with 10% fetal bovine serum (Hyclone Perbio, Bezons, France). The POS-1 cells, originally isolated from a spontaneous osteosarcoma developed in a C3H/HeN mouse, were a kind gift from Dr A Kamijo. 29 They were cultured in RPMI (Lonza) with 10% fetal bovine serum.
Firefly luciferase gene cloning into lentiviral vector
The pGL3-CT plasmid (Promega, Charbonnie`res, France) that contains the complementary DNA encoding firefly luciferase (LucF) was modified by oligonucleotide insertion to replace the HindIII and XbaI sites by BamHI and MluI restriction sites, respectively. Oligonucleotides 5 0 -AGCTACGTGGATCCAGATCTCAGT-3 0 and 5 0 -AG CTACTGAGATCTGGATCCACGT-3 0 containing a BamHI site and the oligonucleotides 5 0 -CTAGTACT GTCGACACGCGTTAGA-3 0 and 5 0 -CTAGTCTAACG CGTGTCGACAGTA-3 0 containing a MluI site were annealed and cloned into the pGL3-CT plasmid. The modified pGL3-CT plasmid was used to excise the LucF gene using BamHI and MluI enzymes. The excised LucF gene was cloned into the pLNT/Sffv-MCS plasmid 30 between the BamHI and MluI sites. The resulting plasmid was designated pLNT-LucF and used to produce lentiviral particles.
Lentiviral production and osteosarcoma cell transduction Lentivirus was produced using the ViraPower Lentiviral Expression System according to the manufacturer's guidelines (Invitrogen Life Technologies, Cergy-pontoise, France). Briefly, 6 Â 10 6 HEK293FT cells (human embryonic kidney cells optimized for viral production) were seeded and transfected 24 h later with 3 mg of the optimized packaging mix, 9 mg of pLNT-LucF and 0.9 mg of pFG12 31 that encodes the enhanced green fluorescent protein (EGFP). Virus-containing supernatants were collected 48 h post-transfection and concentrated 60-fold by ultrafiltration. For titration, serial dilutions of viruscontaining supernatants were tested on HEK293FT cells that were analyzed for EGFP expression 4 days post-infection by flow cytometry (FACSCalibur Flow cytometer, BD Biosciences, Le Pont de Claix, France). Two million EGFP-viral units per ml were typically obtained.
To Alkaline phosphatase activity Total protein was extracted from LucF-OSRGA and OSRGA cells using lysis buffer (NaCl 150 mM, Tris 50 mM, Nonidet P-40 1%, sodium deoxycholate 0.25%, NaF 1 mM, leupeptine 10 mg/ml, aprotinin 10 mg/ml, phenymethylsulfonylfluoride 0.5 mM and glycerol 10%). Total protein concentrations were determined using a LucF-OSRGA cells in 50 ml phosphate buffered saline into the footpad. From developed tumors, 2 Â 2 Â 2-mm 3 fragments were excised and transplanted into naive mice. 13 For fragment insertion, a 5-mm section was made to open the muscle along the tibia, then muscular and subcutaneous wounds were sutured. The tumor volume was quantified by measuring two perpendicular diameters with a vernier calliper and calculated using the formula: (l 2 Â L)/2, where l is the smallest and L the largest diameter).
Bioluminescence imaging
The bioluminescence was measured several times a week after luciferase substrate injection into anesthetized mice. On the basis of 25 g weight, mice were intraperitoneally injected with 250 ml of a Rompun-Ketalar solution (8 and 13%, respectively, in phosphate buffered saline) before intraperitoneal injection of 3 mg D-luciferin (Interchim, Montluc¸on, France) dissolved in 250 ml of water. A Photon Imager (Biospace, Paris, France) was used to measure and visualize the photons released during substrate degradation by the luciferase. The BLI is expressed as counts per minute (c.p.m.) after background subtraction.
Ifosfamide treatment
At 6 days after LucF-POS-1 osteosarcoma transplantation, mice (n ¼ 5) were treated every week for 3 consecutive days with 60 mg per kg ifosfamide (ASTA Medica laboratories, Me´rignac, France) or vehicle only, administered by intraperitoneal injection. Tumor volume was measured twice a week and BLI was measured once.
Radiological and microscanner analyses
Radiographs of tumor-bearing legs were obtained postmortem with a mammography PLANMED Sophie apparatus (SN RAH 40710, Helsinki, Finland). In addition, bone architecture was analyzed for tumor bearing tibia using the high-resolution SkyScan-1072 X-ray micro-computed tomography system for small animal imaging (SkyScan, Kartuizersweg, Belgium).
Histology
Tumor tissues were fixed in 10% buffered formaldehyde, and after embedding in paraffin, 5-mm-thick sections were mounted on glass slides. Sections were stained with Masson trichrom. Analysis of necrotic and fibrotic areas was performed on each section using a DMRXA microscope (Leica, Nussloch, Germany).
siRNA experiments Small interfering RNAs were purchased from Eurogentec, Angers, France. The LucF siRNA was designed to target the luciferase gene sequence 5 0 -CUUACGCUGAGUAC UUCGA-3 0 . The control (CT) siRNA (sense: 5 0 -UUCU CCGAACGUGUCACGUUU-3 0 ) did not show significant homology to any mouse messenger RNA sequence according to BLAST database searches. Small interfering RNAs were combined with carrier DNA (a plasmid containing no eucaryotic expression cassette) and the cationic liposome RPR209120/DOPE as described with the same amount of plasmid DNA pre-mixed with siRNA before addition of the cationic liposome at the appropriate concentration. 26 As this liposome has three positive groups, a ratio of 6 nmol cationic liposome per mg of nucleic acid corresponds to a charge ratio of 6. To determine the best nucleic acid / liposome charge ratio for in vivo transfection, we tested in triplicate a range of siRNA quantities (from 0.05 to 0.4 mg) and ratios (from 2 to 8) on 2 Â 10 3 luciferase-expressing osteosarcoma cells seeded in a 96-well optical bottom plate. Animals bearing a LucF-osteosarcoma were injected intratumorally every 2 days with 2.5-10 mg of siRNA combined with liposomes at ratio 6. The efficiency was evaluated by BLI and tumor volume measurements.
Statistical analysis
All analyses were performed using GraphPad InStat v3.02 software (La Jolla, CA). In vivo experimentation results (ifosfamide and siRNA treatments) were analysed with the unpaired nonparametric Mann-Whitney U test using two-tailed P-values. Results with Pp0.05 were considered significant.
Results
Mouse POS-1 and rat OSRGA cell modification by lentiviral transduction A mixture of luciferase-encoding lentiviral particles (LucF-virus) and EGFP-encoding lentiviral particles (EGFP-virus) was produced. Using a ratio of 10 EGFP viral particles for each POS-1 cell and 50 viral particles for each OSRGA cell, an efficient and homogenous modification of cells was obtained, with, respectively, 97 and 95% of cells expressing EGFP, as determined by flow cytometry ( Figure 1a) . As LucF and EGFP plasmids were used at a ratio of 10:1 for the lentiviral production, it was assumed that the LucF gene was transferred as efficiently as the EGFP gene. The modified POS-1 and OSRGA cells showed stable luciferase activity proportional to cell number over a period of at least 3 months in culture (Figure 1b ), and were designated as LucF-POS-1 and LucF-OSRGA cells. The LucF-OSRGA cells seemed to be more efficiently transduced than LucF-POS-1 cells, as EGFP and luciferase expression was 3.5-and 13-fold higher, respectively, in LucF-OSRGA as compared with LucF-POS-1 cells. We were unable to obtain a higher POS-1 cell transduction efficiency as cells died in culture when a higher multiplicity of infection was used. To maintain the initial heterogeneity and biological properties of osteosarcoma cells, modified cells were maintained without cloning.
Several in vitro tests were next performed to check whether the lentiviral transduction had affected the osteoblastic phenotype of transformed cells. Real-time PCR analyses showed that the expression level of corebinding factor alpha1 (Cbfa-1/Runx-2), which is an essential transcription factor for osteoblast differentiation, was similar between LucF-POS-1 and parental POS-1 cells (Figure 1c siRNA in vivo delivery into osteosarcoma J Rousseau et al naive mice to reproduce the complete osteosarcoma animal models, as previously described.
34,25
LucF-OSRGA osteosarcoma transplanted in nude mice enables early in vivo tumor detection while maintaining osteogenic and osteolytic properties The OSRGA osteosarcoma model was originally developed in male Sprague-Dawley rats. Owing to the large amount of D-luciferin required for BLI detection in rats, we decided to establish a LucF-OSRGA transplant model in immunodeficient mice. For this model, a fragment of a LucF-OSRGA tumor from a footpad was transplanted adjacent to the tibia of recipient mice. Tumor development was observed in all transplanted immunodeficient mice. Bioluminescence was detected as early as day 5 (Figures 2a  and b) , whereas tumors were clinically detected only between day 21 and 38 after tumor implantation (Figure 2c ). Until day 20, the bioluminescence increased progressively, suggesting tumor cell proliferation even in the absence of visible tumor. Between day 21 and 30, bioluminescence stabilized, and finally decreased from day 32 to 51 (2.5-fold decrease). In contrast, the mean tumor volume continued to increase until the animal was killed (day 51). The discrepancy between BLI and tumor volume could be partially explained by necrotic cell death. Indeed, histological analyses showed large necrotic, fibrotic regions (Figure 2d ), which were also observed within unmodified OSRGA tumors. The necrotic, fibrotic areas are included in the measurement of tumor volume, but have a lower luciferase activity than healthy, non-necrotic tumor areas. Finally, the extensive bone remodeling that is normally associated with OSRGA osteosarcoma 25 was similarly observed with LucF-OSRGA tumors. Radiography and microscanner analyses showed characteristic osteolytic lesions and ectopic bone formation along the cortical bone at the tumor implantation site (Figures 2e and f) .
Similar results were obtained for LucF-OSRGA tumors in the footpad of mice: (1) earlier tumor detection by BLI than by measurement of tumor volume, (2) lack of correlation Tumor volume and bioluminescence measurements correlate during osteolytic LucF-POS-1 osteosarcoma development in syngeneic mice Fragments of a primary LucF-POS-1 footpad tumor were transplanted adjacent to the tibia of syngeneic mice. Bioluminescence signals were observed as early as day 6 (Figure 3a and b) , whereas tumors were not measurable at that time (Figure 3c ). Longitudinal analysis showed that bioluminescence signal intensity increased exponentially and correlated with tumor volume. Moreover, such correlation was observed for the LucF-POS-1 footpad tumors as well (data not shown). Histological analyses of transplanted LucF-POS-1 tumors showed minor necrotic, fibrotic regions (Figure 3d ), which were much smaller than those observed within LucF-OSRGA tumors (Figure 2d ). Radiography and microscanner analyses revealed osteolytic lesions resulting in cortical destruction comparable with those observed for parental POS-1 tumors (Figures 3e and f) , suggesting that the interaction between osteoclasts and tumor cells that has been previously described for parental POS-1 cells 14 was maintained for luciferase-expressing POS-1 cells.
Bioluminescence is superior to measurement of tumor volume to reveal LucF-POS-1 osteosarcoma growth inhibition in response to chemotherapy Using the LucF-POS-1 model, in which a good correlation was observed between bioluminescence signal intensity and tumor volume for untreated tumors, we evaluated whether BLI enabled earlier detection of tumor responsiveness to chemotherapy, as compared with the measurement of tumor volume. The conventional antic- siRNA in vivo delivery into osteosarcoma J Rousseau et al ancer drug ifosfamide has previously shown partial efficacy in the treatment of rats bearing OSRGA tumors. 34 In this study, we extended the ifosfamide use in the mouse POS-1 osteosarcoma model. Mice bearing LucF-POS-1 tumors were treated with ifosfamide or vehicle only for 3 consecutive days every week. A correlation between bioluminescence and tumor volume measurements was observed for the vehicle-treated group (Figure 4a ), similar to results described above. In the ifosfamide-treated group, a slow concomitant increase of tumor volume and BLI was observed until day 19 after tumor implantation (Figure 4b ). Between days 12 and 21, the mean tumor volume was significantly lower in the treated group as compared with the untreated group. Statistical analyses were not performed after day 21 as several mice either died or were killed in the untreated siRNA in vivo delivery into osteosarcoma J Rousseau et al group as a result of tumor progression. Therefore, the LucF-POS-1 tumor growth significantly slowed down after one sequence of ifosfamide treatment, and an increase in the survival rate was observed in the treated group (data not shown). Moreover, radiographic analyses of tibia bearing LucF-POS-1 tumor showed a lower rate of bone remodeling in the treated group compared with the untreated group (small osteolytic areas with cortical integrity versus extensive osteolytic areas associated with cortical destruction in untreated control mice; data not shown).
In the ifosfamide-treated group, the stabilization of BLI from day 20 to the end of the experiment was suggestive of a complete inhibition of LucF-POS-1 osteosarcoma growth, whereas tumor volume measurements indicated a slowdown rather than an arrest of tumor growth (Figure 4b) . After day 25, the correlation between bioluminescence and tumor volume was lost within the treated group. Histological analyses of LucF-POS-1 tumors from the ifosfamide-treated group showed more extensive necrotic, fibrotic areas than those of the untreated group (Figure 4c ). These necrotic areas are part of the tumor mass and reflect the response to chemotherapy, but poorly express the luciferase, leading to a discrepancy between BLI and tumor volume measurements.
Luciferase expression can be successfully targeted by siRNA As described above, the development of large necrotic, fibrotic areas observed in LucF-OSRGA tumors resulted in a poor correlation between BLI and tumor volume measurements as tumor development progressed ( Figures  2a, c and d) , whereas a close correlation between these two parameters was observed during LucF-POS-1 tumor development (Figures 3a and c) . Therefore, the latter model was used to establish an in vivo siRNA delivery protocol.
We compared the effects of siRNA directed against luciferase messenger RNA (LucF siRNA) with the effects of control siRNA (CT siRNA) that lacks an messenger RNA target in mouse cells. Small interfering RNAs were formulated with the cationic liposome RPR209129/ DOPE to form lipoplexes that have demonstrated efficient delivery of siRNA targeted toward tumor necrosis factor-alpha in a model of rheumatoid arthritis. 26 This formulation also contained a DNA cargo that was shown to enhance the lipoplexe efficiency. 27 First, siRNA transfections were performed on LucF-POS-1 cells in vitro to determine the most efficient nucleic acid/cationic lipid charge ratio. The highest level of inhibition of luciferase activity (30%) was achieved with 0.1 mg of LucF siRNA formulated in lipoplexes at a charge ratio of 6 as compared with CT siRNA transfections (data not shown). Other LucF siRNA quantities and charge ratios did not result in greater and specific inhibitions. On the basis of these results, mice bearing a LucF-POS-1 osteosarcoma were treated intratumorally with siRNA formulated in lipoplexes at the optimal charge ratio of 6.
In preliminary studies, we tested various quantities of CT siRNA (2.5, 5 or 10 mg) and followed the tumor development. Injections of 2.5 mg CT siRNA did not alter tumor growth, whereas administration of 5 or 10 mg CT siRNA resulted in a significant slowdown of tumor progression as compared with untreated mice. Next, we compared the effects of two 2.5-mg LucF siRNA injections with those of CT siRNA on LucF-POS-1 tumor progression; the first injection was administered when a BLI signal was just detectable (at day 3 after tumor transplantation) and the second injection 2 days later (at day 5). Progression of tumor volume and BLI between day 5 and 7 was compared for the LucF siRNA and CT siRNA-treated groups. As shown in Figure 5a , the fold-increase in tumor volume between day 5 and 7 was similar between the two treatment groups. In contrast, the number of photons detected was significantly (54.5%) lower in the group treated with LucF siRNA, as compared with the group that received CT siRNA (Figure 5b) . Thus, our results indicate that liposomal delivery of siRNA can inhibit gene expression in a specific manner in osteosarcoma tumors.
Discussion
Osteosarcomas are malignant tumors that produce variable amounts of bone or osteoid tissue while simultaneously inducing osteolytic lesions. Owing to this clinical heterogeneity, osteolytic or osteogenic preclinical models are in use to develop and evaluate new therapeutic strategies. For example, the therapeutic association of ifosfamide and zoledronic acid was initially performed in the rat OSRGA model 34 and next transferred to the French clinical trial OS2006. In this study, two osteosarcoma cell lines POS-1 and OSRGA corresponding to, siRNA in vivo delivery into osteosarcoma J Rousseau et al respectively, an osteolytic and an osteogenic model were modified to express the firefly luciferase enzyme to enable in vivo tumor detection by BLI. Preclinical models of luciferase-expressing osteosarcoma were successfully established with conserved physiological and clinical properties. Indeed, LucF-OSRGA-derived osteosarcomas showed a strong osteogenic activity in nude mice, whereas LucF-POS-1-derived osteosarcomas triggered osteolytic lesions in syngeneic mice. In addition, the LucF cell detection by BLI provided new insights into the tumor growth kinetics. The osteosarcomas were detected earlier by bioluminescence than by tumor volume measurement, allowing very early treatment monitoring. Today osteosarcoma response to preoperative chemotherapy is based on histopathologic analysis of tumor resection specimen as defined by Huvos, 35 in which examination of necrotic fibrotic and viable tumor areas serve as prognostic markers. In our preclinical study, BLI measurement better correlated with the estimation of tumor regression by histological analyses than tumor volume measurement. Indeed, ifosfamide treatment led to a slowdown of the mean tumor volume, challenging the treatment efficiency, whereas it led to a strong decrease followed by a stagnation of the mean bioluminescence, indicating a tumor growth arrest. Histological analyses confirmed the isfosfamide treatment efficiency with numerous necrotic fibrotic areas that contribute to the tumor volume but not to the alive tumor expressing the firefly luciferase.
As the discovery in 2001 of the RNAi machinery in mammalian cells and in worms, synthetic siRNAs have emerged as promising new drugs, combining high specificity (sequence-mediated gene silencing) with a homogenous chemical structure. 36 The major challenge lies in developing a way to efficiently deliver siRNA into target cells in patients without significant off-target effects. Using our newly developed LucF-POS-1 osteosarcoma model that showed a good correlation between tumor volume and bioluminescence measurements, we optimized a method for the efficient and specific delivery of siRNA, that is, inducing a significant decrease in bioluminescence using siRNA directed against luciferase, without altering tumor progression. As siRNAs are unstable in serum and need to cross cell membrane, they can be combined with various chemical agents (cationic lipids, polymers or peptides). 37 In this study, the siRNAs were complexed with the cationic liposome RPR209120/ DOPE for in vivo delivery. This chemical agent has proven efficiency to deliver siRNA in a mouse experimental model for rheumatoid arthritis, achieving 50-60% inhibition of the siRNA-targeted gene when administered intravenously. 26 The LucF-POS-1 cells are usually difficult to transfect with chemical agents, and such limit was also observed for RPR209120/DOPE-combined siRNA transfer. However, despite the poor in vitro transfection efficiency, we established an efficient in vivo siRNA delivery method. Intratumoral injections of 2.5 mg siRNA combined with RPR209120/DOPE resulted in a 50% decrease in luciferase expression without interfering with tumor progression. Our experiments indicate that greater quantities of siRNA and RPR209120/DOPE inhibited tumor growth nonspecifically. These nonspecific effects may result from the activation of innate immune responses by nucleic acids, whereas an excessive inflammatory cytokine release can have strong toxic effects in human. 38 Consequently, various strategies are developed to formulate siRNA with lipids to obtain an antitumoral effect through specific gene silencing without triggering an immune response. 39 The formulation of siRNA with the RPR209120/DOPE liposome includes the pre-association of siRNA with a plasmid DNA cargo. Indeed, naked siRNA and siRNA complexed alone in a lipoplexe confer mild or intermediate protection against arthritis, whereas protection was complete with the plasmid DNA cargo formulation. 26 We recently showed that the addition of a DNA cargo in the siRNA formulation has minor effect on the structure of the lipoplexes, whereas the presence of plasmid DNA into the formulation could help the dissociation of the lipoplexes by interaction/competition with cell surface proteoglycans. 27 However, an optimization of the siRNA formulation with the cationic liposome RPR209120/DOPE would be to replace the carrier plasmid for clinical development.
By inducing transient RNAi, a few preclinical studies have shown that sarcoma progression can be reduced by downregulating genes that are implicated in cell cycle control or progression. Wang et al. 20 have observed an inhibition of human osteosarcoma xenografts in which the apurinic/apyrimidinic endonuclease gene has been downregulated by RNAi. For this, they have injected short hairpin RNA expression vectors into tumors. For certain clinical applications, siRNA has advantages over short hairpin RNA vector as smaller amounts of siRNAs are required for efficient delivery into target cells. Naked siRNAs against stathmin, which is an important regulator of microtubule dynamics and overexpressed in various human cancer cells, have been injected into the tail vein of mice bearing xenografted osteosarcoma. 21 They have enabled a slight direct antitumor activity and enhanced significantly the chemosensitivity of osteosarcomas. However, the in vivo inhibition of stathmin has not been demonstrated after siRNA injection. Hu-Lieskovan et al. 19 have treated metastatic Ewing's sarcoma with siRNA directed against the EWS-FLI1 oncogene. In their report, tail vein injections of naked siRNA have shown no therapeutic effect, while injections of these siRNA combined with polyplexes have inhibited tumor growth and human tumor cell engraftment. They have also demonstrated that siRNA-targeted genes (luciferase or EWS-FLI1) were efficiently downregulated in vivo. All together these studies suggest that siRNA could be useful as drug combined with chemotherapeutic or antiangiogenic agents in sarcoma therapies. In addition, they have highlighted the need to demonstrate the effective gene silencing and the absence of indirect antitumor effects of siRNA in vivo.
Numerous studies using recombinant protein have demonstrated that progression of primary or secondary bone tumors depends on molecular and cellular interactions within the bone microenvironment, forming the soil siRNA in vivo delivery into osteosarcoma J Rousseau et al where the seed can grow. 40, 41 In one study using siRNA, a soil-dependent effect was observed. Bisanz et al. 18 reported a strong effect of siRNA directed against integrin subunits combined with liposome on the growth of human prostate tumor in bone, but not on subcutaneaous tumor growth. Similar site-dependent effects can be expected with siRNA directed against RANKL, the major cytokine involved in the vicious cycle between osteolysis and bone tumor progression. In our previous preclinical studies, RANKL blockade was achieved by overexpression of decoy receptors (osteoprotegerin or RANK-Fc) by gene transfer, which resulted in a strong inhibition of osteosarcoma growth. 13, 14 In this study, we demonstrate that siRNA can be successfully used to target a specific gene in osteosarcoma induced in mice. This raises the possibility that RANKL inhibition in osteosarcoma may be achieved using synthetic siRNA, which would be ideal for antitumor therapies due to its ease of manufacturing and the transient nature of its effect.
